FI4019041T3 - Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta - Google Patents
Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta Download PDFInfo
- Publication number
- FI4019041T3 FI4019041T3 FIEP21215762.2T FI21215762T FI4019041T3 FI 4019041 T3 FI4019041 T3 FI 4019041T3 FI 21215762 T FI21215762 T FI 21215762T FI 4019041 T3 FI4019041 T3 FI 4019041T3
- Authority
- FI
- Finland
- Prior art keywords
- car
- cells
- inhibitor
- use according
- leukemia
- Prior art date
Links
- 230000001988 toxicity Effects 0.000 title claims 3
- 231100000419 toxicity Toxicity 0.000 title claims 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 17
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 13
- 102000004889 Interleukin-6 Human genes 0.000 claims 7
- 108090001005 Interleukin-6 Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 206010066476 Haematological malignancy Diseases 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000011519 second-line treatment Methods 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Bioinformatics & Computational Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671482P | 2012-07-13 | 2012-07-13 | |
| US201361782982P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4019041T3 true FI4019041T3 (fi) | 2023-04-03 |
Family
ID=49916566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21215762.2T FI4019041T3 (fi) | 2012-07-13 | 2013-07-12 | Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta |
| FIEP24202493.3T FI4461308T3 (fi) | 2012-07-13 | 2013-07-12 | Car:ien tuumorinvastaisen toiminnan toksisuuden hallinta |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP24202493.3T FI4461308T3 (fi) | 2012-07-13 | 2013-07-12 | Car:ien tuumorinvastaisen toiminnan toksisuuden hallinta |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20150202286A1 (enExample) |
| EP (5) | EP2872171B1 (enExample) |
| JP (6) | JP6382191B2 (enExample) |
| KR (1) | KR102204029B1 (enExample) |
| CN (4) | CN104427997B (enExample) |
| AU (2) | AU2013289967B2 (enExample) |
| BR (1) | BR112015000660A8 (enExample) |
| CA (1) | CA2878928C (enExample) |
| DK (4) | DK2872171T3 (enExample) |
| EA (1) | EA201590210A1 (enExample) |
| ES (4) | ES3032321T3 (enExample) |
| FI (2) | FI4019041T3 (enExample) |
| HR (2) | HRP20230297T1 (enExample) |
| HU (4) | HUE053556T2 (enExample) |
| IN (1) | IN2014DN11155A (enExample) |
| LT (4) | LT3338794T (enExample) |
| MX (2) | MX2015000438A (enExample) |
| PL (3) | PL4461308T3 (enExample) |
| PT (4) | PT4019041T (enExample) |
| SI (2) | SI4019041T1 (enExample) |
| WO (1) | WO2014011984A1 (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872171B1 (en) | 2012-07-13 | 2021-01-06 | The Trustees Of The University Of Pennsylvania | Toxicity management for anti-tumor activity of cars |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| UY35340A (es) | 2013-02-20 | 2014-09-30 | Novartis Ag | Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123 |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| EP3134120B1 (en) | 2014-04-21 | 2024-01-24 | The Children's Hospital of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| KR102804360B1 (ko) | 2014-09-17 | 2025-05-12 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| AU2015330898B2 (en) * | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP6895380B2 (ja) | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| WO2017141243A1 (en) * | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11512289B2 (en) * | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CA2981751A1 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| SG11201708516YA (en) | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CN107708811B (zh) | 2015-04-21 | 2021-04-30 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN108780084B (zh) * | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| EP3708588A1 (en) | 2015-11-27 | 2020-09-16 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
| EP3384294B1 (en) * | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| SG11201804373VA (en) | 2015-12-04 | 2018-06-28 | Novartis Ag | Compositions and methods for immunooncology |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| JP6853514B2 (ja) * | 2015-12-27 | 2021-03-31 | 国立大学法人東海国立大学機構 | 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球 |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018009923A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| MA71266A (fr) * | 2016-03-22 | 2025-04-30 | Seattle Children's Hospital(DBA Seattle Children's Research Institute) | Procédés d'intervention précoce pour prévenir ou améliorer la toxicité |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| WO2018018958A1 (en) | 2016-04-22 | 2018-02-01 | Carsgen Therapeutics Co., Ltd. | Compositions and methods of cellular immunotherapy |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| JP7219376B2 (ja) | 2016-07-15 | 2023-02-08 | ノバルティス アーゲー | キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防 |
| RU2019105693A (ru) * | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
| MX2019003886A (es) | 2016-10-07 | 2019-08-05 | Novartis Ag | Receptores de antigenos quimericos para el tratamiento del cancer. |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| KR20190104528A (ko) * | 2016-12-03 | 2019-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Car-t 세포들 투여를 결정하는 방법 |
| CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| BR112019017767A2 (pt) * | 2017-02-27 | 2020-04-07 | Juno Therapeutics Inc | composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| RU2019133280A (ru) | 2017-03-22 | 2021-04-22 | Новартис Аг | Композиции и способы для иммуноонкологии |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US20200333329A1 (en) * | 2017-05-01 | 2020-10-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted cytokine blockades for car-t therapy |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| WO2018225072A1 (en) * | 2017-06-08 | 2018-12-13 | Enlivex Therapeutics Ltd. | Therapeutic apoptotic cells for cancer therapy |
| JP2020530291A (ja) | 2017-08-10 | 2020-10-22 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法 |
| US11673962B2 (en) | 2017-10-02 | 2023-06-13 | Humanigen, Inc. | Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| AR113777A1 (es) * | 2017-10-18 | 2020-06-10 | Kite Pharma Inc | Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| WO2019144091A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN108300807A (zh) * | 2018-02-07 | 2018-07-20 | 安徽古生物科技有限公司 | 针对第四代嵌合抗原受体car载体pcr鉴定的方法 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| US20210046159A1 (en) * | 2018-03-09 | 2021-02-18 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| AU2019235782A1 (en) * | 2018-03-14 | 2020-10-08 | Celledit Llc | Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy |
| EP3765092A4 (en) * | 2018-03-15 | 2022-01-12 | KSQ Therapeutics, Inc. | GENE CONTROL COMPOSITIONS AND METHODS FOR ENHANCING IMMUNOTHERAPY |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| SG11202010996QA (en) | 2018-05-23 | 2020-12-30 | Nat Univ Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| EP3801563B1 (en) * | 2018-06-01 | 2023-07-12 | Mayo Foundation for Medical Education and Research | Materials and methods for treating cancer |
| SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| CN108949759B (zh) * | 2018-07-23 | 2021-06-01 | 合肥一兮生物科技有限公司 | 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用 |
| CN112739340B (zh) | 2018-07-23 | 2025-05-13 | 海德堡医药研究有限责任公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| SG11202101169PA (en) * | 2018-08-10 | 2021-03-30 | Eutilex Co Ltd | Chimeric antigen receptor that binds hla-dr and car-t cell |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| MX2021002856A (es) * | 2018-09-10 | 2021-05-28 | Humanigen Inc | Metodos para tratar toxicidad relacionada con inmunoterapia utilizando un antagonista de gm-csf. |
| US20220040229A1 (en) * | 2018-10-31 | 2022-02-10 | Humanigen, Inc. | Materials and methods for treating cancer |
| JP2022513062A (ja) * | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| CN120025452A (zh) | 2018-12-12 | 2025-05-23 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| WO2020142815A1 (en) * | 2019-01-07 | 2020-07-16 | Celluris Participações Ltda | Bispecific in tandem receptor car and method for modulating the tumoral microenvironment |
| CN112430579A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 |
| TW202134264A (zh) | 2019-11-26 | 2021-09-16 | 瑞士商諾華公司 | 嵌合抗原受體及其用途 |
| AU2020394441B2 (en) | 2019-11-26 | 2025-11-13 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| TW202144400A (zh) * | 2020-02-20 | 2021-12-01 | 美商凱特製藥公司 | 嵌合抗原受體t細胞療法 |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US12274747B2 (en) | 2021-01-28 | 2025-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4298120A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023004055A1 (en) * | 2021-07-21 | 2023-01-26 | The Cleveland Clinic Foundation | Metabolic and inflammatory markers for car-t cell therapy |
| IL312250A (en) * | 2021-10-27 | 2024-06-01 | Univ Rush Medical Center | Methods for treating the effects of cytokine storms |
| CA3259019A1 (en) * | 2022-02-15 | 2023-08-24 | Kite Pharma Inc | PREDICTION OF ADVERSE EVENTS FROM IMMUNOTHERAPY |
| KR20250089538A (ko) * | 2022-10-20 | 2025-06-18 | 마이크로크리스퍼 피브이티 리미티드 | 면역치료에서의 사이토카인 방출 증후군 감소 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE195022T1 (de) | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US6267722B1 (en) | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| US6656745B1 (en) | 2000-06-02 | 2003-12-02 | Francis X. Cole | Devices and methods for a multi-level, semi-quantitative immunodiffusion assay |
| AU2008207646A1 (en) * | 2001-10-04 | 2008-09-25 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| CN102060806A (zh) * | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| DE602004030586D1 (de) * | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| CA2993715A1 (en) | 2007-05-21 | 2008-11-27 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
| WO2008157282A1 (en) * | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| WO2010065077A2 (en) | 2008-11-25 | 2010-06-10 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
| WO2010075249A2 (en) * | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2504031A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | ANTI-IL-6 ANTIBODIES AND THEIR USE |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| WO2014006586A1 (en) | 2012-07-04 | 2014-01-09 | In & Tec S.R.L. | Hinge for rotatably moving a door, in particular a reinforced door |
| EP2872171B1 (en) | 2012-07-13 | 2021-01-06 | The Trustees Of The University Of Pennsylvania | Toxicity management for anti-tumor activity of cars |
-
2013
- 2013-07-12 EP EP13817210.1A patent/EP2872171B1/en active Active
- 2013-07-12 EA EA201590210A patent/EA201590210A1/ru unknown
- 2013-07-12 LT LTEP18154090.7T patent/LT3338794T/lt unknown
- 2013-07-12 DK DK13817210.1T patent/DK2872171T3/da active
- 2013-07-12 DK DK24202493.3T patent/DK4461308T3/da active
- 2013-07-12 CN CN201380037301.5A patent/CN104427997B/zh active Active
- 2013-07-12 SI SI201332036T patent/SI4019041T1/sl unknown
- 2013-07-12 HU HUE13817210A patent/HUE053556T2/hu unknown
- 2013-07-12 HU HUE21215762A patent/HUE061555T2/hu unknown
- 2013-07-12 PT PT212157622T patent/PT4019041T/pt unknown
- 2013-07-12 AU AU2013289967A patent/AU2013289967B2/en active Active
- 2013-07-12 KR KR1020157003078A patent/KR102204029B1/ko active Active
- 2013-07-12 DK DK21215762.2T patent/DK4019041T3/da active
- 2013-07-12 HR HRP20230297TT patent/HRP20230297T1/hr unknown
- 2013-07-12 FI FIEP21215762.2T patent/FI4019041T3/fi active
- 2013-07-12 PT PT242024933T patent/PT4461308T/pt unknown
- 2013-07-12 LT LTEP13817210.1T patent/LT2872171T/lt unknown
- 2013-07-12 PL PL24202493.3T patent/PL4461308T3/pl unknown
- 2013-07-12 DK DK18154090.7T patent/DK3338794T3/da active
- 2013-07-12 ES ES24202493T patent/ES3032321T3/es active Active
- 2013-07-12 PL PL13817210T patent/PL2872171T3/pl unknown
- 2013-07-12 LT LTEP21215762.2T patent/LT4019041T/lt unknown
- 2013-07-12 EP EP24202493.3A patent/EP4461308B1/en active Active
- 2013-07-12 PT PT138172101T patent/PT2872171T/pt unknown
- 2013-07-12 LT LTEP24202493.3T patent/LT4461308T/lt unknown
- 2013-07-12 HU HUE24202493A patent/HUE072215T2/hu unknown
- 2013-07-12 EP EP20158930.6A patent/EP3721901A1/en active Pending
- 2013-07-12 ES ES18154090T patent/ES2778701T3/es active Active
- 2013-07-12 HR HRP20250822TT patent/HRP20250822T1/hr unknown
- 2013-07-12 BR BR112015000660A patent/BR112015000660A8/pt not_active Application Discontinuation
- 2013-07-12 EP EP21215762.2A patent/EP4019041B1/en active Active
- 2013-07-12 CN CN202010124264.3A patent/CN111467494B/zh active Active
- 2013-07-12 CA CA2878928A patent/CA2878928C/en active Active
- 2013-07-12 MX MX2015000438A patent/MX2015000438A/es active IP Right Grant
- 2013-07-12 US US14/410,659 patent/US20150202286A1/en not_active Abandoned
- 2013-07-12 CN CN201810348463.5A patent/CN108379586A/zh active Pending
- 2013-07-12 CN CN202010124303.XA patent/CN111481667A/zh active Pending
- 2013-07-12 PL PL21215762.2T patent/PL4019041T3/pl unknown
- 2013-07-12 IN IN11155DEN2014 patent/IN2014DN11155A/en unknown
- 2013-07-12 WO PCT/US2013/050267 patent/WO2014011984A1/en not_active Ceased
- 2013-07-12 EP EP18154090.7A patent/EP3338794B1/en not_active Revoked
- 2013-07-12 JP JP2015521838A patent/JP6382191B2/ja active Active
- 2013-07-12 PT PT181540907T patent/PT3338794T/pt unknown
- 2013-07-12 FI FIEP24202493.3T patent/FI4461308T3/fi active
- 2013-07-12 HU HUE18154090A patent/HUE048947T2/hu unknown
- 2013-07-12 SI SI201332104T patent/SI4461308T1/sl unknown
- 2013-07-12 ES ES21215762T patent/ES2941370T3/es active Active
- 2013-07-12 ES ES13817210T patent/ES2859522T3/es active Active
-
2015
- 2015-01-09 MX MX2019014761A patent/MX2019014761A/es unknown
-
2018
- 2018-04-26 JP JP2018085102A patent/JP6563554B2/ja active Active
- 2018-04-26 US US15/963,728 patent/US11273219B2/en active Active
- 2018-05-07 US US15/972,972 patent/US10603378B2/en active Active
- 2018-06-04 AU AU2018203924A patent/AU2018203924B2/en active Active
- 2018-08-09 JP JP2018150287A patent/JP2019006782A/ja not_active Withdrawn
-
2019
- 2019-07-24 JP JP2019136179A patent/JP7034125B2/ja active Active
-
2022
- 2022-02-22 US US17/677,208 patent/US20230013642A1/en not_active Abandoned
- 2022-03-01 JP JP2022030740A patent/JP7682820B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194132A patent/JP2025013518A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4019041T3 (fi) | Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| NZ750426A (en) | Modified t lymphocytes having improved specificity | |
| AR091545A1 (es) | Anticuerpos anti-egfr y usos de los mismos | |
| WO2017066481A8 (en) | Chimeric antigen receptors containing a chlorotoxin domain | |
| AR089083A1 (es) | Anticuerpos para receptor de factor de crecimiento epidermico 3 (her3) | |
| WO2016077840A3 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| AR067517A1 (es) | Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos | |
| FI3737765T4 (fi) | Parannettuja immuunisoluja käyttämällä kahta shRNA:ta ja niitä sisältäviä koostumuksia | |
| BR112015009961A2 (pt) | imunoglobinas anti-vegf/dll4 com duplo domínio variável e uso destas | |
| HK1231487A1 (zh) | 针对cd127的抗体 | |
| HK1203375A1 (en) | Method for treating a gd2 positive cancer | |
| WO2015048547A3 (en) | Methods for using and biomarkers for ampk-activating compounds | |
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| HK1220205A1 (zh) | 修饰的t淋巴细胞 | |
| IL252631B1 (en) | ACTIVIN-ACTRII antagonists and uses for the treatment of anemia | |
| BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
| WO2011110642A3 (en) | Monoclonal antibodies against c-met | |
| MX392618B (es) | Un anticuerpo monoclonal de anti-beta7 para usarse en el tratamiento de un trastorno inflamatorio gastrointestinal. | |
| HK1214752A1 (zh) | 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法 | |
| WO2013023043A3 (en) | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy | |
| JP2019527204A5 (enExample) | ||
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy | |
| WO2013109279A3 (en) | Stabilization of the anti-cd20 antibody rituximab | |
| WO2016014799A9 (en) | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy |